Seraph 100 Microbind Affinity Blood Filter Does Not Clear Antibiotics: An Analysis of Antibiotic Concentration Data from PURIFY-OBS.

Autor: DeLuca JP; Walter Reed Army Institute of Research, Bethesda, Maryland, USA., Selig DJ; Walter Reed Army Institute of Research, Bethesda, Maryland, USA., Vir P; Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA., Vuong CV; Walter Reed Army Institute of Research, Bethesda, Maryland, USA., Della-Volpe J; Institute for Extracorporeal Life Support, San Antonio, Texas, USA., Rivera IM; Department of Medicine, Eisenhower Army Medical Center, Augusta, Georgia, USA., Park C; Department of Surgery, University of Texas Southwestern, Dallas, Texas, USA., Levi B; Department of Surgery, University of Texas Southwestern, Dallas, Texas, USA., Pratt KP; Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, Maryland, USA., Stewart IJ; Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, Maryland, USA.
Jazyk: angličtina
Zdroj: Blood purification [Blood Purif] 2024; Vol. 53 (5), pp. 379-385. Date of Electronic Publication: 2024 Jan 13.
DOI: 10.1159/000531951
Abstrakt: Introduction: Novel hemoperfusion systems are emerging for the treatment of sepsis. These devices can directly remove pathogens, pathogen-associated molecular patterns, cytokines, and other inflammatory markers from circulation. However, significant safety concerns such as potential antibiotic clearance need to be addressed prior to these devices being used in large clinical studies.
Methods: Prospective, observational study of 34 participants undergoing treatment with the Seraph 100® Microbind Affinity Blood Filter (Seraph 100) device at 6 participating sites in the USA. Patients were included for analysis if they had a record of receiving an antibiotic concurrent with Seraph 100 treatment. Patients were excluded if there was missing information for blood flow rate. Blood samples were drawn pre- and post-filter at 1 h and 4 h after treatment initiation. These average pre- and post-filter time-concentration observations were then used to estimate antibiotic clearance in L/h (CLSeraph) due to the Seraph 100 device.
Results: Of the 34 participants in the study, 17 met inclusion and exclusion criteria for the antibiotic analysis. Data were obtained for 7 antibiotics (azithromycin, cefazolin, cefepime, ceftriaxone, linezolid, piperacillin, and vancomycin) and one beta-lactamase inhibitor. Mean CLSeraph for the antibiotics investigated ranged from -0.57 to 0.47 L/h. No antibiotic had a CLSeraph statistically significant from 0.
Discussion/conclusion: The Seraph 100 did not significantly clear any measured antibiotic in clinical samples. These data give further evidence to suggest that these therapies may be safely administered to critically ill patients and will not impact concentrations of administered antibiotics.
(© 2024 S. Karger AG, Basel.)
Databáze: MEDLINE